TY - JOUR
T1 - Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
AU - Quintás-Cardama, Alfonso
AU - Kantarjian, Hagop
AU - Cortes, Jorge
AU - Verstovsek, Srdan
PY - 2011/2
Y1 - 2011/2
N2 - Recent advances in our understanding of the pathogenesis of the Philadelphia chromosome-negative myeloproliferative neoplasms, polycythaemia vera, essential thrombocythaemia and myelofibrosis have led to the identification of the mutation V617F in Janus kinase (JAK) as a potential therapeutic target. This information has prompted the development of ATP-competitive JAK2 inhibitors. Therapy with JAK2 inhibitors may induce rapid and marked reductions in spleen size and can lead to remarkable improvements in constitutional symptoms and overall quality of life. Because JAKs are involved in the pathogenesis of inflammatory and immune-mediated disorders, JAK inhibitors are also being tested in clinical trials in patients with rheumatoid arthritis and psoriasis, as well as for the treatment of other autoimmune diseases and for the prevention of allograft rejection. Preliminary results indicate that these agents hold great promise for the treatment of JAK-driven disorders.
AB - Recent advances in our understanding of the pathogenesis of the Philadelphia chromosome-negative myeloproliferative neoplasms, polycythaemia vera, essential thrombocythaemia and myelofibrosis have led to the identification of the mutation V617F in Janus kinase (JAK) as a potential therapeutic target. This information has prompted the development of ATP-competitive JAK2 inhibitors. Therapy with JAK2 inhibitors may induce rapid and marked reductions in spleen size and can lead to remarkable improvements in constitutional symptoms and overall quality of life. Because JAKs are involved in the pathogenesis of inflammatory and immune-mediated disorders, JAK inhibitors are also being tested in clinical trials in patients with rheumatoid arthritis and psoriasis, as well as for the treatment of other autoimmune diseases and for the prevention of allograft rejection. Preliminary results indicate that these agents hold great promise for the treatment of JAK-driven disorders.
UR - http://www.scopus.com/inward/record.url?scp=79551575494&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79551575494&partnerID=8YFLogxK
U2 - 10.1038/nrd3264
DO - 10.1038/nrd3264
M3 - Review article
C2 - 21283107
AN - SCOPUS:79551575494
SN - 1474-1776
VL - 10
SP - 127
EP - 140
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
IS - 2
ER -